JP2007513903A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513903A5
JP2007513903A5 JP2006543431A JP2006543431A JP2007513903A5 JP 2007513903 A5 JP2007513903 A5 JP 2007513903A5 JP 2006543431 A JP2006543431 A JP 2006543431A JP 2006543431 A JP2006543431 A JP 2006543431A JP 2007513903 A5 JP2007513903 A5 JP 2007513903A5
Authority
JP
Japan
Prior art keywords
permeation enhancer
composition
composition according
aliphatic fatty
terpene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006543431A
Other languages
English (en)
Other versions
JP4842141B2 (ja
JP2007513903A (ja
Filing date
Publication date
Priority claimed from DE10358525A external-priority patent/DE10358525A1/de
Application filed filed Critical
Publication of JP2007513903A publication Critical patent/JP2007513903A/ja
Publication of JP2007513903A5 publication Critical patent/JP2007513903A5/ja
Application granted granted Critical
Publication of JP4842141B2 publication Critical patent/JP4842141B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (14)

  1. ・活性化合物として、環状デプシペプチドおよび/またはプラジカンテル
    ・ピロリドン溶媒
    ・テルペン透過増強剤および/または透過増強剤として作用する脂肪族脂肪酸および/または透過増強剤として作用する脂肪族脂肪アルコール
    を含む組成物。
  2. テルペン透過増強剤としてテルペン炭化水素を含む、請求項1に記載の組成物。
  3. テルペン透過増強剤としてリモネンを含む、請求項2に記載の組成物。
  4. 透過増強剤として作用する脂肪族脂肪酸が、リノール酸またはオレイン酸である、請求項1に記載の組成物。
  5. 透過増強剤として作用する脂肪族脂肪酸がオレイン酸である、請求項1または請求項に記載の組成物。
  6. テルペン透過増強剤および透過増強剤として作用する脂肪族脂肪酸を含む、請求項1に記載の組成物。
  7. テルペン透過増強剤がリモネンであり、透過増強剤として作用する脂肪族脂肪酸がオレイン酸またはリノール酸である、請求項6に記載の組成物。
  8. 透過増強剤として作用する脂肪族脂肪酸がオレイン酸である、請求項7に記載の組成物。
  9. 活性化合物として環状デプシペプチドを含む、請求項1ないし請求項8のいずれかに記載の組成物。
  10. 活性化合物としてエモデプシドを含む、請求項1ないし請求項9のいずれかに記載の組成物。
  11. 環状デプシペプチドおよびプラジカンテルを含む、請求項1ないし請求項9のいずれかに記載の組成物。
  12. エモデプシドおよびプラジカンテルを含む、請求項10または請求項11に記載の組成物。
  13. 活性化合物を、溶媒および必要に応じてさらなる補助剤と混合することを特徴とする、請求項1ないし請求項12のいずれかに記載の組成物の製造方法。
  14. 内寄生生物を制御するための、請求項1ないし請求項12のいずれかに記載の組成物の使用。
JP2006543431A 2003-12-13 2004-11-30 皮膚適用のための殺内寄生生物組成物 Expired - Fee Related JP4842141B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10358525A DE10358525A1 (de) 2003-12-13 2003-12-13 Endoparasitizide Mittel zur topischen Applikation
DE10358525.7 2003-12-13
PCT/EP2004/013552 WO2005055973A2 (de) 2003-12-13 2004-11-30 Endoparasitizide mittel zur topischen applikation

Publications (3)

Publication Number Publication Date
JP2007513903A JP2007513903A (ja) 2007-05-31
JP2007513903A5 true JP2007513903A5 (ja) 2008-01-17
JP4842141B2 JP4842141B2 (ja) 2011-12-21

Family

ID=34638681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006543431A Expired - Fee Related JP4842141B2 (ja) 2003-12-13 2004-11-30 皮膚適用のための殺内寄生生物組成物

Country Status (32)

Country Link
US (1) US7763583B2 (ja)
EP (1) EP1694291B1 (ja)
JP (1) JP4842141B2 (ja)
KR (1) KR101272139B1 (ja)
CN (1) CN1893919B (ja)
AR (1) AR046878A1 (ja)
AT (1) ATE447940T1 (ja)
AU (1) AU2004296537B2 (ja)
BR (1) BRPI0417578B1 (ja)
CA (1) CA2548897C (ja)
CR (1) CR8428A (ja)
DE (2) DE10358525A1 (ja)
DK (1) DK1694291T3 (ja)
ES (1) ES2334920T3 (ja)
GT (1) GT200400264A (ja)
HK (1) HK1102915A1 (ja)
HR (1) HRP20100056T1 (ja)
IL (1) IL176151A (ja)
MX (1) MXPA06006594A (ja)
MY (1) MY142044A (ja)
NO (1) NO20063171L (ja)
NZ (1) NZ547837A (ja)
PE (1) PE20050919A1 (ja)
PL (1) PL1694291T3 (ja)
PT (1) PT1694291E (ja)
RU (1) RU2401108C2 (ja)
SI (1) SI1694291T1 (ja)
TW (1) TWI341202B (ja)
UA (1) UA85574C2 (ja)
UY (1) UY28662A1 (ja)
WO (1) WO2005055973A2 (ja)
ZA (1) ZA200604744B (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
PE20081406A1 (es) * 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
KR20110007242A (ko) * 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 펩티드 조성물 및 그의 제조 방법
WO2010042395A1 (en) * 2008-10-08 2010-04-15 Wyeth Llc Benzimidazole anthelmintic compositions
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
DE102009012423A1 (de) 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
AP2909A (en) 2009-03-17 2014-05-31 Concert Pharmaceuticals Inc Pyrazinoisoquinoline Compounds
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
US8680054B2 (en) * 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
CN102283843A (zh) * 2011-06-29 2011-12-21 梁晓天 一种吡喹酮外用制剂及其制备方法和应用
JP6185930B2 (ja) * 2011-12-21 2017-08-23 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 非晶質エモデプシド含有製剤
WO2014098619A1 (en) * 2012-12-18 2014-06-26 Donaghys Industries Limited Transdermal parasiticidal formulations
WO2015123480A2 (en) * 2014-02-14 2015-08-20 Dsm Ip Assets B.V. Compositions and methods for the prevention and/or treatment of schistosomiasis
ES2975708T3 (es) 2015-01-29 2024-07-12 Novo Nordisk As Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico
JP7045191B2 (ja) 2015-05-20 2022-03-31 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 駆虫性デプシペプチド化合物
JP6943859B2 (ja) 2015-12-28 2021-10-06 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 駆虫性デプシペプチド化合物
JP2020504710A (ja) 2016-11-16 2020-02-13 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 駆虫性デプシペプチド化合物
EP3480195A1 (en) 2017-11-07 2019-05-08 Bayer Animal Health GmbH Method for the synthesis of cyclic depsipeptides
WO2019091975A1 (en) 2017-11-07 2019-05-16 Bayer Animal Health Gmbh Method for the synthesis of cyclic depsipeptides
CN111346046B (zh) * 2020-03-06 2021-07-09 安徽农业大学 一种含莫西菌素注射用缓释凝胶制剂及制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US281292A (en) * 1883-07-17 onslow
DE2362539C2 (de) 1973-12-17 1986-05-07 Merck Patent Gmbh, 6100 Darmstadt 2-Acyl-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isochinoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3619030A1 (de) * 1986-06-06 1987-12-10 Bayer Ag Topisch anwendbare zubereitungen
DE3634755A1 (de) * 1986-10-11 1988-04-14 Bayer Ag Dermale behandlung von wurmerkrankungen der katze mit praziquantel
NO176766C (no) 1989-02-07 1995-05-24 Meiji Seika Kaisha Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
DE4317458A1 (de) 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
DE4317457A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
DE4317432A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
DE4400464A1 (de) 1994-01-11 1995-07-13 Bayer Ag Endoparasitizide Mittel
NZ260018A (en) 1994-03-03 1995-10-26 Bomac Lab Ltd Benzimidazole compositions and anthelmintic compositions
DE19520275A1 (de) * 1995-06-02 1996-12-05 Bayer Ag Endoparasitizide Mittel
US5780487A (en) 1995-08-07 1998-07-14 Amer Moh Samir S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide
DE19601263A1 (de) 1996-01-16 1997-07-17 Bayer Ag Anthelmintische Paste
DE19628776A1 (de) 1996-07-17 1998-01-22 Bayer Ag Oral applizierbare Granulate von Hexahydropyrazinderivaten
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
DE19921887A1 (de) * 1999-05-12 2000-11-16 Bayer Ag Endoparasitizide Mittel
DE19941024A1 (de) 1999-08-28 2001-03-01 Hartmut Klocke Wirkstoffpräparat für tierärztliche Applikation und Verfahren zu seiner Herstellung
US6340672B1 (en) 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation
DE10008128A1 (de) 2000-02-22 2001-08-23 Bayer Ag Endoparasitizide Mittel
DK1197215T3 (da) 2000-10-10 2006-07-10 Wyeth Corp Anthelmintiske sammensætninger
GB0108485D0 (en) 2001-04-04 2001-05-23 Pfizer Ltd Combination therapy
US6893652B2 (en) 2001-08-27 2005-05-17 Wyeth Endoparasiticidal gel composition
NZ542955A (en) * 2003-04-04 2008-07-31 Merial Ltd At least one macrolide anthelmintic compound and a second anthelmintic agent, such as praziquantel, morantel and/or pyrantel, a non-aqueous solvent and a thickening agent to prevent endo- and ectoparasitic infections

Similar Documents

Publication Publication Date Title
JP2007513903A5 (ja)
CA2548897A1 (en) Endoparasiticidal agents for topical application
JP2006271392A5 (ja)
US9707187B2 (en) Composition for enhancing transdermal absorption of a drug and patch preparation
WO2011146936A3 (en) Self-assembled surfactant structures
NZ591261A (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
ECSP034430A (es) Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamcios
WO2007133265A3 (en) Adhesive with alkanoate blend
RU2006122181A (ru) Система трансдермальной доставки никотина
UY27643A1 (es) Formas de dosificación farmacéutica de liberación controlada de un inhibidor de la proteína de transferencia del éster de colesterilo
TW200631597A (en) External use preparation and adhesive preparation thereof
JP2008513467A5 (ja)
AU2001279631A1 (en) Self-emulsifying active substance formulation and use of this formulation
EP1637167A3 (en) New injectable formulations containing progesterone
EP2177531A3 (en) Cell permeable peptide
CA2599334A1 (en) External plaster containing flurbiprofen
ATE413865T1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
WO2006062933A3 (en) Stable compositions of fenofibrate with fatty acid esters
WO2002030467A3 (en) Pharmaceutical composition containing honey for the treatment of wounds
US20140255466A1 (en) Composition for enhancing transdermal absorption of drug and patch preparation
EP2570122A1 (en) Composition for Enhancing Transdermal Absorption of A Drug and Patch Preparation
WO2010020799A3 (en) Compositions for the treatment of neoplastic diseases
EP2570116B1 (en) Composition for enhancing transdermal absorption of a drug and patch preparation
CA2494568A1 (en) Patches containing tulobuterol
UA83036C2 (ru) Фармацевтическая композиция в виде гидрогеля для трансдермального введения в организм действующих веществ